Cancer researchers now have a set of TaqMan gene expression assays designed to detect fusion transcripts using real-time PCR. Certain fusion transcripts are considered rare and are not well characterized; therefore, detecting these rare events using a single technology can deliver ambiguous results. As such, researchers often employ an orthogonal method of validation to confirm results. As a complementary solution to next-generation sequencing (NGS) panels, including the Oncomine Focus Assay, the TaqMan gene expression assays are designed to serve as an orthogonal validation method for confirming NGS results.

Key Applications
Cancer researchers performing fusion transcript detection using an orthogonal method of validation to confirm NGS results.


  • Built from proven TaqMan Assays chemistry
  • Performance guaranteed for all pre-designed assays
  • Consists of a single tube, which contains a probe, forward primer, and reverse primer for each target for use in the simple, fast PCR workflow
  • Use universal cycling conditions – can...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?